510(k) Summary - Tina-quant® RF II Test System

Introduction
According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

Submitter
Roche Diagnostics Corporation
9115 Hague Rd
Indianapolis IN 46250
(317) 521-3831
Contact person: Sherri L. Coenen
Date prepared: August 8, 2003

Device Name
Proprietary name: Tina-quant® Rheumatoid Factors II Test System
Common name: Tina-quant® RF II
Classification name: Rheumatoid Factor Test System

Device description
The Tina-quant® Rheumatoid Factors II Test System is a particle enhanced immunoturbidimetric assay. Latex-bound heat inactivated IgG (antigen) reacts with the RF-antibodies in the sample to form antigen/antibody complexes which, following agglutination, are measured turbidimetrically.

Intended use
Immunoturbidimetric assay for the in vitro quantitative determination of rheumatoid factors in human serum and plasma on automated clinical chemistry analyzers. Measurements may be used as an aid in the diagnosis of rheumatoid arthritis.

Predicate Device
We claim substantial equivalence to the currently marketed Tina-quant® Rheumatoid Factors II Test System. (K002609).
Reagent Summary

The following table describes the similarities and differences between the Tina-quant® Rheumatoid Factors II Test System and the predicate device.

<table>
<thead>
<tr>
<th>Topic</th>
<th>Tina-quant® RF II (K002609)</th>
<th>Tina-quant® RF II (Modified Device)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intended Use</td>
<td>Immunoturbidimetric assay for the quantitative in vitro determination of rheumatoid factors in human serum on automated clinical chemistry analyzers. Measurements may be used as an aid in the diagnosis of rheumatoid arthritis.</td>
<td>Immunoturbidimetric assay for the quantitative in vitro determination of rheumatoid factors in human serum and plasma on automated clinical chemistry analyzers. Measurements may be used as an aid in the diagnosis of rheumatoid arthritis.</td>
</tr>
<tr>
<td>Method</td>
<td>Particle-enhanced immunoturbidimetric assay</td>
<td>Same</td>
</tr>
<tr>
<td>Sample type</td>
<td>Serum</td>
<td>Serum Li/Na Heparin, Na₂/K₂/K₃ EDTA-Plasma</td>
</tr>
<tr>
<td>Measuring Range</td>
<td>3 - 120.0 IU/ml</td>
<td>7 - 103 IU/ml</td>
</tr>
<tr>
<td>Expected Values</td>
<td>&lt; 14 IU/ml</td>
<td>Same</td>
</tr>
</tbody>
</table>
Ms. Sherri L. Coenen  
Regulatory Submissions, Centralized Diagnostics  
Roche Diagnostics Corporation  
9115 Hague Road  
P.O. Box 50457  
Indianapolis, Indiana 46250-0457

Re: k032535  
Trade/Device Name: Tina-quant® RF II Test System  
Regulation Number: 21 CFR § 866.5775  
Regulation Name: Rheumatoid factor immunological test system  
Regulatory Class: II  
Product Code: DHR  
Dated: August 8, 2003  
Received: August 18, 2003

Dear Ms. Coenen:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

Steven I. Gutman, M.D., M.B.A.
Director
Office of In Vitro Diagnostic Device Evaluation and Safety
Center for Devices and Radiological Health

Enclosure
Indications for Use Statement

510(k) Number (if known): N/A K032535

Device Name: Tina-quant® RF II Test System

Indications For Use:

Immunoturbidimetric assay for the in vitro quantitative determination of rheumatoid factors in human serum and plasma on automated clinical chemistry analyzers. Measurements may be used as an aid in the diagnosis of rheumatoid arthritis.

(Please do not write below this line - continue on another page if needed)

Concurrence of CDRH, Office of Device Evaluation (ODE) Prescription Use OR Over-The-Counter Use

(Per 21 CFR 801.109) (Optional Format 1-2-96)

Division Sign-Off

Office of In Vitro Diagnostic Device Evaluation and Safety

510(k) 16325 35